iBRD4-BD1 is selective BRD4 bromodomain inhibitor. iBRD4-BD1 has inhibition activity for BRD4 bromodomain with an IC50 value of 12 nM. iBRD4-BD1 can be used for the research of inflammation and oncology.
iBRD4-BD1 has affinity and selectivity for the BET-family BRD4-BD1 with an IC50 value of 12 nM[1].
iBRD4-BD1 has affinity and selectivity for the BET-family BRD4-BD2, BRD3-BD1, BRD3-BD2, BRD2-BD1 and BRD2-BD2 with IC50 values of 16 μM, 1.0 μM , 75 μM , 280 nM and 7.1 μM, respectively[1].
iBRD4-BD1 (0-50 μM; 72 h) has cytotoxicity with an EC50 value of 2.3 μM in MM.1S cells[1].
References:
[1]. Anand Divakaran, et al. Development of an N-Terminal BRD4 Bromodomain-Targeted Degrader. ACS Med Chem Lett. 2022 Sep 29;13(10):1621-1627.
















